Testing a new drug for sudden vision loss from nerve inflammation
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This study tests whether a new medication called privosegtor can help restore vision in people who recently experienced sudden vision loss in one eye due to optic nerve inflammation. You would receive the study drug early after your symptoms start, when treatment may be most effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old
- You experienced sudden vision loss in one eye for the first time
- Your vision loss started within the last 12 days
- You do not have other serious health conditions that might affect the study results or your safety
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the eye-to-brain visual pathways work in people who have had optic neuritis symptoms for less than 4 weeks. It may help researchers better understand neuro-inflammatory (nerve inflammation) disorders and improve future care.
This study is checking whether a new 2022 set of diagnostic rules correctly identifies optic neuritis, which is inflammation of the nerve that connects your eye to your brain. If you've recently had vision problems and doctors suspect this condition, participating could help confirm the diagnosis and shape future care.
This trial tests a drug called efgartigimod for people having their first episode of optic neuritis (inflammation of the optic nerve). The goal is to see if it can help protect your vision better than standard treatment alone.
This Phase 2 trial tests whether clemastine can help regrow the protective covering around the optic nerve after acute optic neuritis (an inflammation-related vision problem). It may help improve vision recovery and signal how well “remyelination” happens.
This study uses a new type of MRI to look at the optic nerve in people who have recently had optic neuritis (inflammation of the nerve that connects the eye to the brain). The goal is to see if this MRI can give doctors better information about the condition, which may help guide treatment.
This study tests whether starting plasma exchange early (right after steroids) is better than waiting to see if steroids are enough for people with severe optic neuritis or transverse myelitis. It may help preserve vision or movement by stopping inflammation sooner.
Hear when a new Optic Neuritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.